FDA Takes Tougher Line on Fast-Tracked Drugs

December 6, 2022

(Wall Street Journal) – The Food and Drug Administration is taking a harder line on its program that fast-tracks drug approvals based on preliminary evidence, spurring GSK PLC, Roche Holdings AG and other drugmakers to remake plans for their drugs or pull them from the market. Under the accelerated-approval program, the FDA clears the use of prescription medicines faster than it normally would. The agency relies on preliminary data to make the decision, but asks companies to conduct follow-up studies to confirm that the drug works. Yet companies haven’t always done the studies—or been willing to pull drugs when a follow-up study failed to show a true benefit. (Read More)